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Disorders Center and University of Alabama at Birmingham, Birmingham, AL, USAElevated serum ferritin concentrations are common in clinical without an elevated TS have hyperferritinemia related to inﬂam-
practice. In this review, we provide an approach to interpreting
the serum ferritin elevation in relationship to other clinical
parameters including the patient history, transferrin saturation,
serum concentrations of alanine, and aspartate aminotransfer-
ases (ALT, AST), testing for HFE mutations, liver imaging, liver
biopsy, and liver iron concentration. We used observations from
a large series of patients with hepatic iron overload documented
by liver iron concentration measurement from two referral prac-
tices as a gold standard to guide the interpretation of the predic-
tive values of non-invasive iron tests. Three case studies illustrate
common problems in interpreting iron blood tests.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Elevated serum ferritin concentrations are common. The cause of
an elevated ferritin concentration is usually increased ferritin
synthesis (including acquired/genetic conditions with or without
iron overload) or increased release of ferritin from damaged cells
(Table 1). A clue to the cause of the elevation is often the accom-
panying clinical setting. For example, an isolated elevation of
serum ferritin <1000 lg/L with a normal transferrin saturation
(TS) in the context of daily alcohol consumption or obesity is a
common presentation. Another group of patients with an isolated
elevation of serum ferritin <1000 lg/L and normal TS values have
hyporegenerative anemia untreated with transfusion (usually
due to renal insufﬁciency, chronic disease, or marrow failure),
malignancy, or chronic inﬂammation of diverse etiologies. In
either situation, iron overload is usually not present and thus
diagnosis and management of the disorders that contribute to
hyperferritinemia is indicated. The diagnostic approach to ele-
vated serum ferritin concentrations in patients who also have
elevated serum concentrations of liver enzymes is more compli-
cated. Genetic hemochromatosis is often considered when evalu-
ating an elevated ferritin. Regardless of this, most patientsJournal of Hepatology 20
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abnormalities (e.g., obesity).
Reference concentrations of serum ferritin and TS vary across
laboratories due to differences in analytical techniques and refer-
ence populations; age and sex are also important determinants of
these measures. A large, multi-ethnic, multi-racial screening
study of iron overload in North Americans recruited in primary
care settings deﬁned that serum ferritin concentrations greater
than 300 lg/L in men and greater than 200 lg/L in women were
elevated [1]. By deﬁnition, TS values greater than 50% in men and
greater than 45% in women were deﬁned as elevated. Analysis of
race/ethnicity groups within this large cohort revealed that mean
SF and percentages of participants with elevated SF were signiﬁ-
cantly greater in blacks, Asians, and Paciﬁc Islanders than in
whites. Mean TS values were greatest in Asians and Paciﬁc Island-
ers, intermediate in whites, and lowest in African Americans. This
indicates that ‘‘elevated’’ serum ferritin or TS concentrations are
probably not always the indicators of disease, although the
biological basis and clinical signiﬁcance of these race/ethnicity
differences in iron phenotypes are incompletely understood.Using transferrin saturation to interpret elevated serum
ferritin level
Serum ferritin concentrations are often measured to investigate
fatigue, possible liver disease, anemia, malignancy, or other
conditions.Many clinicians interpret the serum ferritin concentra-
tion togetherwith TS to determine if iron overload, iron deﬁciency,
or subnormal ironmobilization for erythropoiesis is present. Thus,
many clinicians rely on inferencesmade fromTSmeasurements as
an aid to the diagnosis of a variety of abnormalities [2,3].
In a large population screening study, we have demonstrated
that there is signiﬁcant biological variability in serum TS [4]. In
64,230 participants, a non-fasting TS >45% in women and >50%
in men had a sensitivity of 75% and speciﬁcity of 95% in the
detection of C282Y homozygotes. This variability decreases the
reliability and speciﬁcity of TS as a test to clarify the diagnostic
signiﬁcance of elevated serum ferritin concentrations. Within-
person biological variability in iron test values has been reported
previously; diurnal ﬂuctuations in test values have been described
primarily for serum iron measurements [4,5]. TS is a calculated
value determined as the quotient of the serum iron level divided
by one of the following: total iron-binding capacity; unsaturated11 vol. 55 j 453–458
Table 1. Mechanism of hyperferritinemia in selected disorders.
Increased apoferritin (or L ferritin) synthesis/secretion: chronic ethanol ingestion; malignancy (malignant histiocytosis; 
carcinomas of lung, breast, ovary, and kidney; lymphoma; liposarcoma); Gaucher disease; reactive histiocytosis; hereditary 
hyperferritinemia-cataract syndrome 
Increased ferritin release from injured cells: hepatic steatosis and steatohepatitis; chronic viral hepatitis; massive liver necrosis 
due to sepsis, acute hepatitis, or toxic injury; autoimmune disorders; acute and chronic infections; acute myocardial infarction; 
splenic infarct 
Increased ferritin synthesis due to iron overload: HFE and other types of hemochromatosis; heritable and acquired anemias 
-bus(reeblanoitidartfonoitsegnironorilatnemelppusmorfnoitprosbanoridesaercni;siseioporhtyreevitceffenihtiwdetaicossa
Saharan African Natives); transfusion iron overload; parenteral iron overload; aceruloplasminemia 
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Fig. 1. The relationship between transferrin saturation and hepatic iron
overload in C282Y homozygotes (d) and non-homozygotes (s).
Reviewiron-binding capacity + serum iron concentration; or serum trans-
ferrin concentration multiplied by a constant. Liver disease some-
times causes low serum transferrin concentrations that may lead
to increased TS without iron overload. The higher variability of TS
than the serum iron level may be due to the fact that measure-
ment of TS is a two-step, rather than a single-step, test. It has been
reported thatmostHFE C282Y homozygotes have persistently ele-
vated TS, and that false positive tests in non-homozygotes would
likely return to normal on a second test [6]. This was the previous
rationale for using two TS tests (ﬁrst test random, second test fast-
ing) for the presumptive diagnosis of hemochromatosis before
proceeding to more speciﬁc diagnostic tests, including liver
biopsy or DNA-based testing. Regardless, this and other studies
failed to conﬁrm that fasting iron tests had greater speciﬁcity
for the diagnosis of HFE C282Y-linked hemochromatosis than iron
tests drawn without regard to fasting [2,3]. In addition, variability
of TS measurements in this study was similar in homozygotes and
non-homozygotes [4]. The second fasting value was as likely to
increase as to decrease, and regression to the mean is the most
likely explanation for this phenomenon. Fasting as a condition
for testing adds a level of complexity and inconvenience to a
screening program. In addition, any biochemical test with such
wide biological variation is unlikely to be an ideal screening test.
Relationship between transferrin saturation and liver iron
concentration
Elevated TS is an important prerequisite for iron loading of hepa-
tocytes typical of hemochromatosis due to mutations in genes
that encode HFE, hemojuvelin, transferrin receptor 2, and hepci-
din. Elevated TS depends partly on increased iron absorption,
because food iron deprivation causes TS to decrease [7] and sup-
plemental iron increases TS. Increased release of iron from mac-
rophages into plasma also contributes to elevated plasma iron
and TS concentrations. Overall, the elevated TS that may be
observed in relatively young persons suggests that iron absorp-
tion is increased. Acute infections, menses, recent blood donation
may temporarily reduce TS concentrations in persons with exces-
sive hepatocyte iron deposition [8]. Due to this variability, we
recommend testing Caucasian patients with serum ferritin
>1000 lg/L for the HFE C282Y mutation.
We investigated the relationship between an elevated TS and
liver iron concentration further. Using observations from two
tertiary referral centers (London, Ontario and Birmingham,
Alabama), we tabulated data from patients who underwent
measurement of TS and liver iron concentration (Fig. 1). In the Ala-
bama samples, liver iron concentrations were measured in
patients with iron overload initially determined by liver iron454 Journal of Hepatology 201histochemical grading criteria. In the London, Ontario samples,
liver iron was measured on a more diverse group, because many
of the patients participated in a study of MRI and liver iron [9].
Patients from both locations were separated into two groups:
HFE C282Y homozygotes and other cases. Diagnoses in these
patients included hemochromatosis, non-HFE iron overload,
juvenile hemochromatosis, alcoholic liver disease, fatty liver, hep-
atitis C, and hepatitis B. Becausemost patients do not undergo rou-
tine liver biopsy, this sample does not represent the general
population. We analyzed these data using receiver operator char-
acteristic (ROC) curves; we calculated positive likelihood ratios for
predicting hepatic iron overload (LIC >40 lmol/g) (Table 2). From
these results, we conclude that: (1) TS predicts hepatic iron over-
load better in C282Y homozygotes than in non-homozygotes; and
(2) some patients with a normal TS and an elevated serum ferritin
concentration have iron overload proven by liver biopsy.Assessment of patients with an elevated ferritin concentration
and a non-elevated transferrin saturation
In this setting, it is useful to measure serum concentrations of AST,
ALT, alkaline phosphatase (AP), gamma-glutamyl transpeptidase
(GGT), HBsAg, and anti-HCV; assess alcohol history and body mass
index; and performabdominal ultrasonography. If a patient has ele-
vatedserumconcentrationsofhepatic enzymes, thenextquestion is
whether the elevated serum ferritin level is the sequel of hepatocyte
necrosis or, less likely, whether iron overload caused the liver dam-
age [10,11]. Typical patients with hyporegenerative anemia have
normal serum concentrations of hepatic enzymes, and anemia is1 vol. 55 j 453–458
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rare in persons with hemochromatosis due to HFE C282Y homozy-
gosity who have not been treated with phlebotomy.
Obesity or fatty liver detected by ultrasonography suggest the
presence of steatohepatitis. Chronic alcohol consumption may be
suspected based on the clinical history and an elevated level of
GGT. In patients with viral hepatitis B or C, serum ferritin is often
elevated but usually does not indicate iron overload. A clinical syn-
drome has been described in France associated with insulin resis-
tance and features of the metabolic syndrome [12,13]. Patients
with dysmetabolic syndrome usually have elevated serum ferritin
concentrations and a normal TS. Liver biopsy in such patients usu-
ally demonstrates iron in Kupffer cells and steatosis; insulin resis-
tance in suchpatientsmaydecreasewithphlebotomy therapy [14].
Obesity, diabetes mellitus, dyslipidemia, and hypertension are
other common although not diagnostic features of this syndrome.
Hereditary hyperferritinemia–cataract syndrome (HHCS) is
caused by heterogeneous mutations in the iron-responsive
element (IRE) of L-ferritin that reduce the binding afﬁnity of
iron-responsive proteins (IRPs) to IREs and thereby diminish the
negative control of L-ferritin (but not H-ferritin) synthesis. This
leads to the constitutive up-regulation of ferritin L-chain synthesis
characteristic of HHCS. Serum ferritin concentrations are elevated
and relatively constant; TS is normal. Patients with HHCS do not
develop iron overload, although common HFE mutations, espe-
cially H63D, may occur in HHCS patients coincidentally. L-ferritin
deposition in the ocular lens causes bilateral cataracts at an early
age [15–17]. It may be possible to have an elevated ferritin on this
basis without cataracts [18]. The concurrence of hyperferritinemia
and cataract do not establish the diagnosis of HHCS [19]. Although
routine genetic testing to verify HHCS is usually not feasible, dem-
onstration of hyperferritinemia and cataract syndrome in two
or more members of the same kinship is usually diagnostic [19].
Aceruloplasminemia is a rare genetic syndrome due to muta-
tions in the CP gene that encodes ceruloplasmin. This condition is
associated with normal TS, hyperferritinemia, and iron overload;
retinal abnormalities; and prominent neurological problems.
Anemia is uncommon. Aceruloplasminemia can be distinguished
from Wilson disease by the absence of ceruloplasmin in the
serum, by the absence of excess urinary copper, and by the
absence of excess storage copper in the liver [20,21].
Ferroportin is an iron transport protein and the receptor for
hepcidin. ‘‘Loss-of-function’’ mutations of the SLC40A1 gene that
encodes the ferroportin result in an uncommon, iron overload dis-
order characterized by normal TS, elevated serum ferritin concen-
tration, and hepatic iron overload. This condition is inherited as an
autosomal dominant trait. Ferroportin normally occurs at the
basolateral surfaces of enterocytes, macrophages, hepatocytes,
and placental syncytiotrophoblasts. In patients with a pathogenic
SLC40A1mutation, ferroportin multimers consists of both normalTable 2. Receiver operating curve assessment of transferrin saturation to
predict hepatic iron overload.
Sensitivity
(%)
Specificity
(%)
>55%* (n = 371)
TS for iron overload
 81  73
>50%  (n = 371)  85  69
>45 (n = 371) 89  61
>55%  in C282Y homozygotes 92  40
(n = 209)
⁄Iron overload is deﬁned as a liver iron concentration >40 lmol/g dry weight.
Journal of Hepatology 201and abnormal molecules, causing a dominant negative effect of
the mutant SLC40A1 allele that prevents normal function of the
wild-type (normal) ferroportin. Excessive iron is typically depos-
ited in macrophages in the liver, spleen, bone marrow, and lymph
nodes; decreased iron mobilization from macrophages decreases
serum iron and TS values [22]. ‘‘Gain-of-function’’ SLC40A1
mutations, in contrast, result in iron overload that is usually
associated with elevated TS, hyperferritinemia, and parenchymal
iron deposition similar to that of HFE hemochromatosis.
A trial of clinical observation
There are many patients in whom observation and follow-up is
more appropriate than an invasive investigation or a trial of phle-
botomy. It is informative to observe whether the serum ferritin
concentration is stable over time. Stable serum ferritin concentra-
tions are typical of hyperferritinemia in some patients with HFE
hemochromatosis, patients of certain race/ethnicity groups, and
persons with HHCS. In patients with hepatic steatosis or steato-
hepatitis or alcohol-inducedhyperferritinemia, serum ferritin con-
centrations typically ﬂuctuate greatly. Progressively increasing
serum ferritin concentrations suggest iron overload. During an
interval of observation, there are opportunities to repeat the TS.
Management of non-iron overload causes of
hyperferritinemia
Treatment of hyperferritinemia involves management of disor-
ders that results in increased synthesis of apoferritin or cell injury.
Interventions, such as alcohol abstinence, improved diabetes con-
trol, weight reduction, or lowering triglyceride concentrations
with diet and medications may reduce serum ferritin concentra-
tions during the observation period. Treatment of hyporegenera-
tive anemia, causes of chronic inﬂammation, malignancy, viral
hepatitis, or other non-iron overload causes of hyperferritinemia
can reduce serum ferritin concentrations and substantiate provi-
sional diagnoses of the cause(s) of hyperferritinemia. Treatment
of hyperferritinemia in persons with HHCS is not indicated.
MRI scanning to detect iron overload
MRI scanning has been used to estimate liver iron concentrations
indirectly. Overall, MRI technology for iron quantiﬁcation is
improving, but requires a dedicated radiology team and appropri-
ate machine-speciﬁc calibration. MRI scanning is better at detect-
ing and quantifying severe hepatic iron overload than mild iron
overload usually associated with mild elevations of serum ferritin
concentrations [23,24].
Trial of phlebotomy
One diagnostic criterion for iron overload is a trial of phlebotomy;
this method was typically used before other methods were
devised. It was assumed that a patient had signiﬁcant iron over-
load if they could tolerate, e.g., 20 weekly phlebotomies without
developing anemia. It has been estimated that a 500 ml phlebot-
omy removes 0.25 g of mobilizable body iron. If the patient devel-
oped anemia after a few phlebotomies, it was assumed that the
elevated serum ferritin value was due to inﬂammation or other
non-iron overload cause, rather than to iron overload, because
many normal persons have sufﬁcient storage iron to support this
level of phlebotomy. Quantitative phlebotomy has great utility1 vol. 55 j 453–458 455
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today; its few adverse effects include venous access, phlebitis,
vasovagal symptoms, anemia, and the costs and potential incon-
venience of arranging treatments. The positive aspects of this
approach to measuring body iron stores are that the patient feels
that something is being done to correct their laboratory abnor-
malities. Many patients report positive physical and mental
effects after phlebotomy. An alternative to arranging weekly phle-
botomy therapy is to suggest that the patient be a voluntary blood
donor every 2–3 months [25]. Patients with HHCS should not be
treated with phlebotomy. Some patients with iron overload due
to ‘‘loss-of-function’’ SLC40A1 mutations reconstitute circulating
erythrocyte concentrations very slowly after phlebotomy treat-
ments and should be managed with relatively low phlebotomy
volumes and long intervals between treatments.
The choice of observation, MRI, phlebotomy, or liver biopsy is
based on clinical judgment, patient preferences, and local
resources. There is not always a preferred pathway and different
approaches may suit different patients.Genetic testing
HFE genotyping is often used to test patients with an elevated
serum ferritin level. Some HFE C282Y homozygotes, and less
commonly HFE H63D homozygotes and compound heterozygotes
(HFE C282Y/H63D) develop iron overload secondary to a genetic
abnormality in iron absorption and metabolism [1]. An increasing
number of pathogenic mutations in other iron related genes
(hemojuvelin, hepcidin, ferroportin, transferrin receptor 2) haveFig. 2. A liver biopsy in an 88 year C282Y homozygous woman with severe iron ove
456 Journal of Hepatology 201been identiﬁed, but there is no widely available commercial test-
ing, if any, for these mutations [26]. In many of the rare cases of
non-HFE iron overload, the genes most likely involved must be
deduced from clinical features in the patient and his/her family
members. Even after the probable causative gene is identiﬁed
by these provisional methods, sequencing of the gene, rather than
mutation-speciﬁc analysis, is often required. In many cases, there
are no abnormal ﬁndings, because there are heritable forms of
iron overload for which no explanatory gene or mutation has
yet been reported. Furthermore, it is becoming increasingly difﬁ-
cult to differentiate between genetic polymorphisms and muta-
tions with functional and clinically signiﬁcant implications. For
a clinician, it can be helpful to test siblings and children of index
patients for iron overload (TS, serum ferritin level) in this setting
to screen for an unusual iron overload disorder. The study of
genomics is rapidly advancing and large scale high-throughput
genetic sequencing is becoming widely available (exome and
NextGen sequencing, total genome sequencing). The storage
and interpretation of these huge volumes of data, their costs,
and the genetic counseling that would be provided to the patient
and their family as an accompaniment to such testing are a great
future challenge, although whether such maneuvers will be fea-
sible diagnostic tools for many patients is unproven.Liver biopsy
Percutaneous liver biopsy is a well-established method for eval-
uation of iron overload [27] and concomitant liver disease (Fig. 2).rload but without liver ﬁbrosis. (PERLS Prussian Blue stain).
1 vol. 55 j 453–458
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The safety of the procedure has been well-documented [28] and
accepted by hepatologists, although other physicians and some
patients are reluctant to accept or recommend the procedure.
In patients who have isolated hyperferritinemia, liver biopsy is
often used to exclude iron overload. Liver biopsy is also useful
for staging steatohepatitis, alcoholic liver disease, or viral hepati-
tis, or to diagnose liver disease that cannot be identiﬁed with
non-invasive methods. A liver biopsy is not routinely recom-
mended to assess iron overload in patients with elevations of
serum ferritin <1000 lg/L, because the risks of the procedure
may outweigh the possibility that a diagnosis will be made that
would change management recommendations [29,30].Case study 1
A 39 year-old woman was referred to liver clinic because she had
serum ferritin of 1822 lg/L. She is a native of the Philippine
Islands with no known European ancestors. She denies any alco-
hol use and has no history of liver diseases or hepatitis. Initial
investigations included AST 72 IU/L, ALT 123 IU/L, bilirubin
9.7 lmol/L, hemoglobin 138 g/L, MCV 92, platelets 314  103/
lL, INR 1.0, albumin 45 g/L, HBsAg negative, anti-HCV negative,
TS 47%, and repeat serum ferritin 2913 lg/L. She has a body mass
index of 32 kg/m2 and an abdominal ultrasound suggesting fatty
inﬁltration of the liver without splenomegaly or ascites. HFE
mutation analyses did not detect C282Y or H63D.
Clinical commentary
Serum ferritin concentration >1000 lg/L is an indication for further
investigations because this level of ferritin has beenassociatedwith
increased riskofhepaticﬁbrosis.HFE-linkedhemochromatosis is an
unlikely diagnosis in a Filipino, although European colonization
could account for HFE C282Y in that geographic region. A clinical
diagnosis of steatohepatitis seems likely, although the ferritin ele-
vation is more elevated than usually expected. Although the TS is
within the reference range, with what degree of certainty does this
exclude iron overload? Options to consider at this point include:
liver biopsy with hepatic iron concentration; MRI imaging with
indirect estimate of liver iron concentration; trial of phlebotomy;
and further observation and monitoring.
The patient has already had a period of observation and the
serum ferritin level is rising. Thus, we would not consider this
option. A trial of phlebotomy is commonly done in community
practice. If the serum ferritin elevation is not due to iron over-
load, the patient will not tolerate the treatment, and will prob-
ably develop anemia after 3–4 units of blood are removed by
phlebotomy. MRI scanning to estimate liver iron concentration
is feasible and yields good estimates of liver iron content in
centers with a special interest in this technique. This would
be a reasonable option, if available. In this case, a liver biopsy
was performed; the specimen revealed severe steatohepatitis
without iron overload or ﬁbrosis. Liver iron concentration
was 17 lmol/g (reference 0–40 lmol/g). This case illustrates
that serum ferritin elevation may be extreme in persons with
severe liver inﬂammation (non-alcoholic steatohepati-
tis = NASH). Her normal TS may have been a clue to the
absence of iron overload, but there can be marked biological
variability in TS values. In patients without HHCS, serum ferri-
tin can be composed of different ferritin moieties including gly-
cosylated ferritin, a protein secreted by macrophages, and/or
tissue ferritins or ferritin light- or heavy-chains released fromJournal of Hepatology 201damaged cells. Isoferritin analysis is not a practical diagnostic
tool to differentiate serum ferritin of iron overload from that
of inﬂammation or HHCS. The ferritin iron concentration has
also been studied as a diagnostic test, but was tedious and
never reached widespread clinical use despite initially
promising results. The correlations of concomitant markers of
inﬂammation such as C-reactive protein (CRP) or erythrocyte
sedimentation rate (ESR) with serum ferritin of inﬂammation
have been inconsistent. Nonetheless, markedly elevated values
of CRP or ESR suggest that hyperferritinemia is probably due
to inﬂammation or infection. Phlebotomy has been studied as
a treatment for steatohepatitis [14,31] and can reduce serum
ferritin concentrations; a beneﬁcial effect on liver ﬁbrosis or
long-term outcomes has not been clearly established. In this
context, persons with HFE C282Y may beneﬁt more from phle-
botomy than those without this common HFE mutation [32].Case study 2
A 55 year-old Scottish woman complained of fatigue. She was
told by a friend that fatigue is a symptom of iron overload in
some patients, and she asked her physician to perform iron tests.
Her serum ferritin level was 4400 lg/L. She has no known liver
diseases or family history of liver disease. She lives with her
identical twin sister. She consumes 2–3 alcoholic drinks daily.
Two weeks after the initial test, her serum ferritin level was
2307 lg/L; TS was 53%; AST, ALT, and GGT concentrations were
223, 172, and 582 IU/L, respectively; and HBsAg and anti-HCV
were negative. Abdominal ultrasound was normal. Her twin
sister volunteered for blood testing that showed a serum ferritin
level of 217 lg/L and TS 29%. Testing for the C282Y and H63D
mutations of the HFE gene was normal in both twins.
Clinical commentary
We have screened approximately 30,000 patients for hemochro-
matosis in our community, and it interests us that a member of
the general public suggests iron overload as a cause of fatigue
rather than iron deﬁciency. In this unusual case, the demonstration
that an identical twin did not have an elevated serum ferritin con-
centration was a helpful diagnostic tool to exclude HFE hemochro-
matosis or other types of iron overload in the index twin, although
there were other risk factors (alcohol). Elevations of AST > ALT are
more typical of alcoholic liver disease than hemochromatosis. Ele-
vated GGT values are also typical of chronic alcohol consumption.
The TS in this index twin was within the reference range, whereas
it is expected that a patient with iron overload and serum ferritin
of 4400 lg/L would have a markedly elevated value of TS. A liver
biopsy was performed in the index twin that demonstrated severe
alcoholic hepatitis without visible iron staining. Liver iron concen-
tration was normal (17 lmol/g; reference 0–40 lmol/g). The
patient admitted that she was depressed and had abused alcohol
daily. She stopped drinking after the initial serum ferritin of
4400 lmol/g was detected; after two weeks of alcohol abstinence,
serum ferritin decreased to 2307 lg/L. After 4 months of absti-
nence, the serum ferritin level decreased to 257 lg/L.
Case 3
An asymptomatic 55 year-old Caucasian physician was referred
for evaluation of serum ferritin 660 lg/L. He was obese and drank
two glasses of wine daily. TS was 40%, and serum concentration1 vol. 55 j 453–458 457
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of ALT and AST were 58 and 37 IU/L, respectively. Testing for HFE
C282Y and H63D mutations showed that he is a H63D heterozy-
gote. The patient was told not to worry that the serum ferritin
level was likely due to inﬂammation due to fatty liver or to stim-
ulation of ferritin synthesis induced by regular alcohol intake. He
decided to become a regular blood donor; after donation of six
units, his serum ferritin was 77 lg/L.
This is a common clinical scenario, and mild elevations of
serum ferritin (300–1000 lg/L) are frequent in clinical practice.
The usual risk factors are daily alcohol consumption and fatty
liver. The cause of the elevation is often not clearly established,
or may be multifactorial, and invasive testing with liver biopsy
is not recommended in such patients. It is paradoxical that if
the serum ferritin level is elevated due to inﬂammation that it
decreases with phlebotomy, although phlebotomy may have
anti-inﬂammatory effects, including the removal of relatively
small amounts of iron that participate in causing tissue injury.
Key Points  
Approximately 90% of patients with hyperferritinemia 
encountered in routine medical practice do not have iron 
overload 
Serum ferritin levels greater than the upper reference 
limit are often encountered in well persons of sub-
Saharan Native African descent or Asian/Pacific Islander 
descent 
Mutation analysis to detect common HFE mutations is 
commercially available, and such testing is most useful in 
evaluating European whites with hyperferritinemia. 
Hyperferritinemia remains unexplained after evaluation in 
many patients 
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